Table 3.

Data for participants who had a significant improvement in visual function [i.e., change (Δ) outside of test-retest variability listed in table 1 or qCSF ROC value ≥97.5%] at both post-treatment (post-tx) assessments following TES or electro-acupuncture (EA). Also listed are these participants’ characteristics, such as age in years, self-reported onset age of initial symptoms of nyctalopia or night vision loss in years, self-reported onset age of initial indications of visual field (VF) loss in years, female (F) or male (M) gender, and presumed genetic mutation inheritance type based on family history of RP (i.e., AD: autosomal dominant, AR: autosomal recessive).

ID	Age	Onset nyctalopia	Onset VF loss	Gender	Race	Genetic	Intervention	Eye(s)	Test	Baseline	Δ Post-tx 1	Δ Post-tx 2
1	44	13	8	F	Caucasian	AD	TES	OS	logMAR VA	1.53	0.41	1.01
2	47	16	24	M	Black	AR	TES	OS	GVF: V4e	0.71	0.31 (104%)	0.33 (114%)
2							TES	OS	logMAR VA	1.14	0.27	0.41
2							TES	OS	qCSF AULCSF	0. 02	0.12 (97.5% ROC)	0.13
3	34	birth	birth	F	Asian Indian	AR	TES	OD	qCSF AULCSF	0. 02	0.16 (100% ROC)	0.16
3							TES	OS	qCSF AULCSF	0. 01	0.09 (99.9% ROC)	0.08
3							TES	OU	qCSF AULCSF	0. 03	0.08 (100% ROC)	0.13
4	40	4	25	M	Hispanic	AR	TES	OD	GVF: V4e	0.54	0.26 (82%)	0.40 (151%)
4							TES	OD	GVF: III4e	−0.54	0.58 (276%)	0.56 (259%)
5	46	birth	8	M	Caucasian	AR	EA	OD	AdaptDx nasal	0.25	1.16 log units	1.00
5							EA	OD	AdaptDx sup.	0. 56	0.89 log units	1.03
6	58	birth	16	M	Hispanic	AR	EA	OS	qCSF AULCSF	0. 68	0.21 (98.5% ROC)	0.17
6							EA	OU	qCSF AULCSF	0. 67	0.26 (99.5% ROC)	0.21
6							EA	OU	qCSF filter	0.36	0.24 (99.5% ROC)	0.16